Publications by authors named "L Rolfe"
Article Synopsis
- The report talks about how drinking alcohol is increasing in the UK and causing more liver disease, which makes people go to the hospital a lot.
- It suggests that the UK Government should make new rules to help reduce overall drinking, like bringing back certain taxes and setting a minimum price for alcohol.
- It also highlights the need to address obesity (being very overweight) because it leads to many health issues, including liver disease and cancers, and mentions that new medicines for hepatitis C are showing promise.
Purpose: Pancreatic cancer has a poor prognosis and limited treatment options. Approximately 9% of pancreatic cancers harbor a germline or somatic or () mutation. Because poly (ADP-ribose) polymerase inhibitors have significant activity in -mutant ovarian and breast cancers, RUCAPANC investigated the efficacy and safety of rucaparib in -mutant pancreatic cancer.
View Article and Find Full Text PDFArticle Synopsis
- The report discusses the serious problems caused by too much alcohol, being overweight, and liver diseases in the UK, with a focus on recommendations to help fix these issues.
- Alcohol abuse is on the rise, causing more people to get sick and lose years of their lives, while obesity is also a growing issue affecting over 60% of adults.
- Even though new medicines are helping people with hepatitis C, more needs to be done to find and help those who are at high risk, especially in poorer areas of the country.
Objective: An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcinoma (HGOC).
Methods: Eligible patients from Study 10 (NCT01482715) and ARIEL2 (NCT01891344) who received a starting dose of oral rucaparib 600mg twice daily (BID) with or without food were included in these analyses. The integrated efficacy population included patients with HGOC and a deleterious germline or somatic BRCA1 or BRCA2 (BRCA1/2) mutation who received at least two prior chemotherapies and were sensitive, resistant, or refractory to platinum-based chemotherapy.
Rucaparib is a potent, oral, small-molecule PARP inhibitor. This phase I-II study was the first to evaluate single-agent oral rucaparib at multiple doses. Part 1 (phase I) sought to determine the MTD, recommended phase II dose (RP2D), and pharmacokinetics of oral rucaparib administered in 21-day continuous cycles in patients with advanced solid tumors.
View Article and Find Full Text PDF